1 completed, 1 not yet recruiting, 1 withdrawn. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Withdrawn 1 |
Follow apabetalone: new trials by email Literature Review of apabetalone trials Research Report on apabetalone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis apabetalone, Placebos - Kidney Failure, Chronic | Phase 1 / Phase 2 | Not yet recruiting | Resverlogix Corp | 44 | 2024-11-22 | 2023-11-15 |
| Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease RVX000222 - Fabry Disease | Phase 1 / Phase 2 | Withdrawn | Resverlogix Corp | 2022-11-22 | 2023-11-18 | |
| Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol RVX000222, Placebo - Dyslipidemia, Atherosclerosis | Phase 1 / Phase 2 | Completed | Resverlogix Corp | 72 | 2008-09-01 | 2022-11-04 |
Cardiovascular Diseases (2) · Acute Coronary Syndrome (1) · Atherosclerosis (1) · Dyslipidemias (1) · Fabry Disease (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1)
Resverlogix Corp (3)
Canada (1) · United States (1)
Allan Gordon, MD, PhD (1) · Michael West, MD (1)